InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 0.001 (14.29%)+
Announcement
Release
20 Mar 2026 9:49AM
Price at Release
$0.004
Full Release
download
Summary
AdAlta Limited, a biotechnology company listed on the ASX under the ticker 1AD, announced that it has secured a new composition of matter patent for its anti-fibrotic product AD-214 in Canada. This patent strengthens the protection of AD-214 in all major commercial markets, including the United States, European Union, and Japan, with an expiry set for 2036. The protection extends to therapeutic and diagnostic applications involving fibrotic diseases such as Idiopathic Pulmonary Fibrosis. AdAlta is pursuing further patent applications related to dosing and treatment methods which could extend the protection until 2043. The i-body technology, intrinsic to AD-214, is central to its development and application.
Key Points
  • AdAlta Limited granted a Canadian patent for AD-214.
  • The patent, titled 'CXCR4 binding molecules', expires on January 8, 2036.
  • AD-214 is protected in major markets including the US, EU, Japan, and Canada until 2036.
  • Additional patent applications for AD-214 could extend protection to 2043.
  • AD-214 focuses on treating lung and kidney fibrotic diseases.
  • AdAlta's i-body technology is a key component of AD-214.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.